ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS

摘要:

For a while, it seemed that we lived in a world of 'Prozac' nations. The hype surrounding 'Prozac' ['Fluoxetine'] during the 1990s helped combat the stigma associated with depression, and, partly as a result, the number of people diagnosed with the condition increased markedly. In the UK, for example, the number of prescriptions for antidepressants rose from 9 million in 1991 to 22 million in 2000. That meant huge sales of leading antidepressants worldwide [seetable]. But is the bubble about to burst? New research from Datamonitor, an independent market analysis company, revealed that psychiatrists are losing confidence in the clinical effectiveness of leading antidepressants. Datamonitor comments that drug companies need to invest in further research, using outcome measures that reassure physicians and patients that second-generation antidepressants are safe and effective, to take advantage of this huge demand.Table. Breakdown of the global antidepressant market by country 1999-2000

ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS

摘要:

Eagerly awaited preliminary results from the OVERTURE*study have demonstrated that the experimental vasopeptidase inhibitor omapatrilat ['Vanlev'] is as effective as the ACE inhibitor enalapril ['Vasotec'] in the treatment of moderate-to-severe heart failure. Data presented at a late-breaker symposium at the 51st Annual Scientific Sessions of the American College of Cardiology (ACC) [Atlanta, US; March 2002] showed a 6% reduction in the combined incidence of mortality and hospitalisation for heart failure with omapatrilat, compared with enalapril; the difference was not statistically significant. Furthermore, the incidence of angioneurotic oedema [angioedema], a potentially life-threatening adverse event, was higher in omapatrilat recipients than in patients treated with enalapril. This echoed recently disclosed results from the landmark OCTAVE**study, in which the incidence of angioneurotic oedema was also higher with omapatrilat than with enalapril, when the two drugs were evaluated in patients with hypertension.

ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS